Engineering Next-Generation Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Therapeutics for Solid Tumors
PrecisionAxis Bio is a preclinical-stage biotechnology company developing next-generation TRAIL-based therapeutics for solid tumors. Our approach is based on the development of highly stabilized leucine zipper (LZ)-TRAIL fusion proteins designed to enhance TRAIL apoptotic potency, stability, and therapeutic potential.
Our earlier research demonstrated that engineered LZ-TRAIL fusion proteins exhibit:
· Enhanced Stability: Stabilized LZ-TRAIL forms highly stable homotrimers with melting temperatures exceeding 80°C.
· 100-Fold Greater Apoptotic Potency: Engineered LZ-TRAIL demonstrated approximately 100-fold greater potency than that of clinical-grade TRAIL in cell-based assays.
· Extended Biological Activity: Engineered LZ-TRAIL demonstrated a markedly prolonged functional half-life in circulation, extending it from approximately 3.5 minutes for recombinant wild-type TRAIL to up to 10 hours.
· Robust Antitumor Efficacy: Low-dose LZ-TRAIL significantly suppressed tumor growth in mouse models without detectable treatment-related toxicity.
Our long-term objective is to advance engineered LZ-TRAIL therapeutics and develop innovative strategies to treat thera
Advancing Next-Generation Cancer Therapies
PrecisionAxis Bio is actively seeking strategic partnerships, academic collaborations, and investment opportunities to advance our next-generation TRAIL-based therapeutics for solid tumors. Contact us to explore how we can collaborate to advance these programs toward clinical development
Engineering Leucine-Zipper-TRAIL: Augmenting Therapeutic Potency and Stability for Clinical Application
Achieving a 100-fold increase in cytotoxic potency and dramatically extended half-life in the bloodstream compared to clinical-grade TRAIL
PrecisionAxis’ technology overcomes the dual limitations that halted previous clinical TRAIL candidates: extreme structural instability and poor pharmacokinetics. By engineering a Leucine-Zipper (LZ)-TRAIL homotrimer, we successfully extended the therapeutic half-life to the 4–8 hour range, a 100-fold improvement over the 3.5-minute half-life of recombinant TRAIL. This optimized structural design yields a highly stable trimer with a melting temperature (Tm) of 81.1°C, as validated by SEC and DSC analysis.
This enhanced molecular stability translates to a 100-fold increase in cytotoxic potency across diverse cancer cell lines compared to clinical-stage TRAIL (dulanermin/TRAIL.0). In vivo, our platform achieved 75% tumor growth inhibition (TGI) at a low-dose (5 mg/kg) without the hepatotoxicity historically associated with modified death receptor ligands. This work establishes the high-potency, stable protein scaffold that serves as the foundation for our entire clinical immunotherapy pipeline.
To advance the Leucine-Zipper (LZ)-TRAIL platform toward clinical translation, we replaced the yeast-derived GCN4-pII trimerization motif with a proprietary human-derived LZ sequence. This Department of Defense (DoD)-funded research successfully minimized the risk of clinical immunogenicity without compromising the molecule's structural integrity or functional activity. Biophysical characterization via Differential Scanning Calorimetry (DSC) confirmed a melting temperature (Tm) of 80.3°C, ensuring high thermodynamic stability equivalent to our first-generation GCN4-pII-LZ-TRAIL construct.
Sedimentation equilibrium centrifugation (SEC) validated that the humanized LZ-TRAIL chimera maintains a stable homotrimeric state. Importantly, this humanized variant retains the 100-fold potency of the original GCN4-pII-LZ-TRAIL version, exhibiting equivalent efficacy in suppressing tumor growth in vivo. This conversion eliminates the potential for an adverse immune response while providing a stable, potent, and 'human-ready' therapeutic scaffold for our next-generation LZ-TRAIL-armored T cell therapies.
Frequently asked questions
Can't find an answer? Don't hesitate to reach out
What is PrecisionAxis Bio’s core mission?
PrecisionAxis Bio is a preclinical-stage biotechnology company dedicated to developing next-generation TRAIL-based therapeutics for solid tumors. Our mission is to advance innovative treatments through precision protein engineering, enhancing therapeutic potency, stability, and biological activity to address the challenges of treatment-resistant cancers.
What is the primary problem PrecisionAxis is solving?
Many solid tumors remain difficult to treat because cancer cells can resist apoptosis, a natural process of programmed cell death. PrecisionAxis Bio is focused on developing engineered TRAIL-based therapeutics with enhanced potency, stability, and biological activity to improve the effectiveness of apoptosis-based cancer treatment strategies.
What is the TRAIL platform and why is it revolutionary?
TRAIL is a naturally occurring component of the human immune system that preferentially induces apoptosis (programmed cell death) in cancer cells while generally sparing healthy cells. It acts by binding death receptors DR4 and DR5 on susceptible cells. However, conventional TRAIL has limited stability and a short circulating half-life. Incorporating a leucine zipper (LZ) domain stabilizes TRAIL's biologically active trimeric structure, substantially enhancing its stability and apoptotic potency. These improvements provide a foundation for developing next-generation TRAIL-based therapeutics for solid tumors.
What is the proof that this engineering works?
Our earlier research demonstrated that engineered LZ-TRAIL fusion proteins exhibit approximately 100-fold greater apoptotic potency than clinical-grade TRAIL in cell-based studies. These proteins form highly stable trimers with melting temperatures exceeding 80°C and retain substantial circulating apoptotic activity 24 hours after injection. Importantly, LZ-TRAIL significantly suppressed tumor growth in preclinical mouse models without detectable treatment-related toxicity under the experimental conditions. Together, these findings provide experimental evidence supporting the development of stabilized LZ-TRAIL proteins as potential therapeutics for solid tumors.
Are there potential applications of TRAIL beyond cancer treatment?
Yes. Beyond its role in cancer-cell apoptosis, TRAIL is a naturally occurring regulator of immune responses and has been implicated in several autoimmune and inflammatory diseases. Published studies suggest that TRAIL signaling can influence pathogenic immune cell activity, inflammation, and tissue protection. However, the therapeutic potential of conventional recombinant TRAIL has been limited in part by its short circulating half-life and biological instability. Our engineered LZ-TRAIL fusion proteins offer substantially enhanced stability, apoptotic potency, and prolonged biological activity, providing a promising basis for investigating LZ-TRAIL-based therapies beyond oncology.
Which autoimmune diseases could benefit from TRAIL-based therapeutics?
Published research has implicated TRAIL signaling in several autoimmune and inflammatory diseases, including Type 1 Diabetes (T1D), Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA), and Multiple Sclerosis (MS). Studies have investigated TRAIL's potential roles in regulating autoreactive immune cells, controlling inflammation, and protecting tissues affected by autoimmune responses. These findings suggest opportunities to investigate whether stabilized LZ-TRAIL fusion proteins could offer therapeutic advantages over conventional recombinant TRAIL.
What is known about the safety of engineered LZ-TRAIL therapeutics?
Our preclinical studies demonstrated that engineered LZ-TRAIL fusion proteins significantly suppressed tumor growth in mouse models without detectable treatment-related toxicity. In addition, we developed humanized LZ-TRAIL variants by replacing nonhuman leucine zipper sequences with human-derived motifs, aiming to reduce potential immunogenicity while preserving protein stability and apoptotic potency. These findings provide an encouraging foundation for further therapeutic development and safety evaluation.